Key Highlights

  • Madrigal beat on Revenue ($364.3 million versus $352.5 million consensus) and loss per share, yet fell 9.8% and 5.2% on two separate occasions to close at $467.32.
  • The commercial story is intact, more than 50,000 patients on therapy and a narrowing operating loss, but SG& Amp ;A of $289.4 million equalled 79% of net sales in the quarter.
  • P/E is meaningless for an unprofitable company; at about 8.4 times trailing sales, the multiple assumes the F4c cirrhosis expansion lands and GLP-1 competition stays contained.
  • Madrigal Pharmaceuticals published second-quarter results at last closing that cleared Wall Street 's bar on both lines.

A beat the market refused to buy

Madrigal Pharmaceuticals ( Nasdaq :MDGL) published second-quarter results at last closing that cleared Wall Street's bar on both lines. Rezdiffra, resmetirom, the thyroid hormone receptor-beta agonist that in March 2024 became the first therapy the FDA approved for MASH with liver fibrosis, booked $364.3 million in net sales, up 71% from $212.8 million a year earlier and ahead of the $352.5 million consensus reported by TheFly. The net loss of $1.99 a share was narrower than the $2.23 analysts had modeled. Chief executive Bill Sibold told investors the company is "still at the beginning of one of the largest opportunities in biotechnology."

Buyers were unmoved. The shares fell 9.83% on results day and a further 5.23% on 31 July, closing at $467.32. Volume hit 1.49 million shares on 30 July against a recent daily norm closer to 250,000. Bank of America trimmed its target to $543 from $553 on 31 July while keeping a Neutral rating, the only Sell-Side move in the tape's direction.

Price context: a round trip from the highs

At $467.32 the stock sits roughly 24% below its 52-week high of $615.00, though still well above the $286.44 low. Before the results, aggregated market data put the 12-month gain at 85.9% against the 29 July close of $546.88, and the consensus target from 17 analysts at $680.60, a figure struck before the selloff. That site's overview and statistics pages lagged its own price history table during this research; the closes used here come from the history file, current through 31 July. On 23.06 million shares outstanding, the last close implies a Market Value near $10.8 billion.

What Rezdiffra has actually built

The Franchise is real and it is scaling fast. More than 49,000 patients were on therapy at 30 June, up from 42,250 at 31 March and 36,250 at the end of 2025; Madrigal said the base passed 50,000 during July. Trailing-twelve-month sales are close to $1.3 billion, from $958.4 million for all of 2025. First-half revenue of $675.6 million nearly doubled the $350.1 million of a year earlier. Rezdiffra also holds a conditional European Marketing authorization granted for noncirrhotic MASH with F2-F3 fibrosis, with a country-by-country rollout that began in Germany; Madrigal does not break out ex-US revenue.

Gross-to-net is where a specialty launch of this size can quietly leak value. The 10-Q for the quarter shows $175.8 million of sales-deduction reserves at 30 June, $152.3 million of that in rebates and co-pay assistance and $23.5 million in chargebacks and prompt-pay discounts. Five customers accounted for 77% of gross sales, normal for US specialty distribution, but a reminder of concentrated channel power.

Reading the second-quarter numbers

Cost of sales jumped to $40.0 million from $9.1 million, reflecting royalties owed to Roche and inventory write-downs, still leaving gross Margin near 89%. R&D rose to $91.2 million from $54.1 million, including $25.0 million of one-time business-development payments. The line that did the damage was SG&A: $289.4 million against $196.9 million, driven by an expanded endocrinology field force and direct-to-consumer Advertising . Madrigal is spending 79 cents of SG&A for every dollar of net sales.

Even so, the operating loss narrowed to roughly $56 million from $92.7 million in the first quarter, and cash, equivalents and marketable securities edged up to $838.9 million from $817.9 million at 31 March, against $988.6 million at the end of 2025. A $500 million Blue Owl Facility signed in July 2025, $350 million drawn, backstops the Balance Sheet . The company issues no formal revenue guidance, which leaves quarterly prints to do all the talking.

The cirrhosis prize and the confirmatory clock

Rezdiffra's approval is conditional in both major markets. In the US, Accelerated Approval must be converted through positive outcomes data; Madrigal's filings restate that obligation without giving a date. The clearer catalyst is MAESTRO-NASH OUTCOMES, the phase 3 trial in compensated MASH cirrhosis (F4c), which the company has said should deliver topline data in 2027.

Supporting evidence so far is suggestive rather than definitive: in the MAESTRO-NAFLD-1 open-label extension, the share of patients classified as higher risk for clinically significant portal hypertension fell from 75% at baseline to 54.5% at year two, and real-world data showed half of patients achieving at least a 25% improvement in liver stiffness over about nine months. Three newly issued patents cover F2-F3 weight-threshold dosing to 2045 and F4c treatment to 2042. Behind Rezdiffra sit more than ten programs, including MGL-2086, an oral GLP-1 that began phase 1 dosing in June 2026 and is explicitly designed for combination with resmetirom.

The bull argument

Wells Fargo initiated coverage at Overweight days before the print, seeing peak Rezdiffra sales above $7 billion. The case rests on a diagnosed-and-treated MASH population that remains a small fraction of the addressable pool, a drug with no oral competitor in its label, a European market opening up, sequential growth of 17% quarter on quarter, and an operating loss that is shrinking while revenue compounds. Net patient additions actually accelerated, about 6,000 in the first quarter, about 6,750 in the second.

The bear argument

Percentage growth is decelerating by arithmetic necessity: 127% year on year in the first quarter, 71% in the second. Fourth-quarter 2025 sales of $321.1 million were followed by a sequential decline to $311.3 million in the first quarter, so the ramp is not linear. More importantly, the competitive moat is thinning. Novo Nordisk's semaglutide won US accelerated approval in the same noncirrhotic F2-F3 MASH population in August 2025 on the strength of its ESSENCE program, arriving with a vastly larger cardiometabolic sales force. Novo then bought Akero Therapeutics and its FGF21 analog efruxifermin for up to $5.2 billion, closing in December 2025, while Roche acquired 89bio and pegozafermin in October 2025. Madrigal is now a single-product mid-cap competing against two of the largest balance sheets in pharma, and spending like it.

Valuation without Earnings

A price-to-earnings ratio is not meaningful here: Madrigal is loss-making, with roughly $309 million of losses over the past twelve months and consensus 2026 EPS of negative $6.52. On sales, the 31 July close implies about 8.4 times trailing revenue and roughly 7 times the $1.50 billion consensus for 2026, with Enterprise value near $10.3 billion after $838.9 million of cash and $347 million of Debt . Those are not demanding multiples for 71% growth; they are demanding if growth halves again and SG&A does not.

What to watch

The answer to the question in the headline is nuanced. Rezdiffra's absolute expansion is not cooling, patient adds and sequential revenue both improved. What has cooled is investors' tolerance for buying that growth at $289 million a quarter of selling cost while two GLP-1 giants build MASH franchises. Third-quarter results, due late October, will show whether patient additions hold above 6,000 and whether SG&A finally flattens.

Upcoming Catalysts

  • Q3 2026 results, expected late October 2026. Net patient additions, sequential sales and whether commercial spending flattens.
  • MAESTRO-NASH OUTCOMES topline in compensated cirrhosis, guided to 2027. The single largest swing Factor for the addressable population.
  • MGL-2086 phase 1 data. First read on Madrigal's own oral GLP-1 and the combination strategy.
  • European reimbursement progress beyond Germany. Ex-US revenue is not yet broken out and would be a new growth line.

Principal Risks

  • Accelerated approval is conditional. US full approval depends on positive outcomes data; a failure would put the label itself at risk.
  • GLP-1 encroachment. Semaglutide is approved in the same F2-F3 population and Novo now owns efruxifermin, while Roche owns pegozafermin.
  • Single-product concentration. Essentially all revenue comes from one medicine sold through five customers representing 77% of gross sales.
  • Spending outruns sales. SG&A grew 47% year on year; if revenue growth decelerates faster than costs, breakeven recedes and the $838.9 million cash balance is finite.
  • No guidance. Without a company outlook, quarterly prints alone set expectations, amplifying Volatility around each report.

Conclusion

Madrigal beat on revenue ($364.3 million versus $352.5 million consensus) and loss per share, yet fell 9.8% and 5.2% on two separate occasions to close at $467.32. Set against that: US full approval depends on positive outcomes data; a failure would put the label itself at risk. That tension shows up in the valuation: P/E is meaningless for an unprofitable company; at about 8.4 times trailing sales, the multiple assumes the F4c cirrhosis expansion lands and GLP-1 competition stays contained. The next real test: Net patient additions, sequential sales and whether commercial spending flattens.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.